The Board of Directors of SyntheticMR has resolved to carry out a directed new issue of 1,250,000 shares, at a subscription price of SEK 48 per share, entailing proceeds of SEK 60 million before transaction costs.
The Directed Share Issue was oversubscribed and a number of Swedish and international institutional investors, including certain existing shareholders, participated in the transaction. Among those, Nortal Investments AB, Invium Partners, Swedbank Robur Fonder, Handelsbanken Fonder, Coeli Asset Management AB, Nordea Fonder, Brohuvudet AB and Funds managed by Aktia Asset Management.
Strengthen the financial position and execute commercialization strategy
SyntheticMR intends to use the net proceeds from the Directed Share Issue to strengthen its financial position and continue to execute on the company’s commercialisation strategy. This includes invest in commercial resources and increase penetration in existing and new customer segments, further establishing the recurring revenue business model and workflow improvements to be standard of care, strengthen and accelerate research and product development, including the next generation of 3D SyMRI, and expand product offering into additional body part applications, accelerate market access in the US, EU, India, Japan and expand into new markets such as Brazil, Canada, China, South Korea and Southeast Asia, and further scale-up of resources and capacity within M&A.
Photo of Ulrik Harrysson, CEO, SyntheticMR
